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ate severity within 72 h. CHIMES-E (Extension) aimed at eval-
uating the effects of the initial 3-month treatment with 
MLC601 on long-term outcome for up to 2 years.  Methods: 
All subjects randomized in CHIMES were eligible for CHIMES-
E. Inclusion criteria for CHIMES were age  ≥ 18, baseline Na-
tional Institute of Health Stroke Scale of 6–14, and pre-stroke 
modified Rankin Scale (mRS)  ≤ 1. Initial CHIMES treatment al-
location blinding was maintained, although no further study 
treatment was provided in CHIMES-E. Subjects received 
standard care and rehabilitation as prescribed by the treat-
ing physician. mRS, Barthel Index (BI), and occurrence of 
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 Abstract 
 Background: The CHInese Medicine NeuroAiD Efficacy on 
Stroke recovery (CHIMES) study was an international ran-
domized double-blind placebo-controlled trial of MLC601 
(NeuroAiD) in subjects with cerebral infarction of intermedi-
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medical events were ascertained at months 6, 12, 18, and 24. 
The primary outcome was mRS at 24 months. Secondary out-
comes were mRS and BI at other time points.  Results: 
CHIMES-E included 880 subjects (mean age 61.8 ± 11.3; 36% 
women). Adjusted OR for mRS ordinal analysis was 1.08 (95% 
CI 0.85–1.37, p = 0.543) and mRS dichotomy  ≤ 1 was 1.29 
(95% CI 0.96–1.74, p = 0.093) at 24 months. However, the 
treatment effect was significantly in favor of MLC601 for mRS 
dichotomy  ≤ 1 at 6 months (OR 1.49, 95% CI 1.11–2.01, p = 
0.008), 12 months (OR 1.41, 95% CI 1.05–1.90, p = 0.023), and 
18 months (OR 1.36, 95% CI 1.01–1.83, p = 0.045), and for BI 
dichotomy  ≥ 95 at 6 months (OR 1.55, 95% CI 1.14–2.10, p = 
0.005) but not at other time points. Subgroup analyses 
showed no treatment heterogeneity. Rates of death and oc-
currence of vascular and other medical events were similar 
between groups.  Conclusions: While the benefits of a 
3-month treatment with MLC601 did not reach statistical sig-
nificance for the primary endpoint at 2 years, the odds of 
functional independence defined as mRS  ≤ 1 was significant-
ly increased at 6 months and persisted up to 18 months after 
a stroke.  © 2015 S. Karger AG, Basel 
 Introduction 
 Stroke is a major cause of death and disability with 
only a limited number of treatment options to improve 
functional outcome after stroke, including thrombolytic 
therapy, early use of aspirin, decompression craniectomy 
for malignant infarcts, stroke unit care, and constraint-
induced movement therapy  [1] . Strategies using neuro-
protectants have failed in many clinical trials  [2] . As many 
still remain disabled even after rehabilitation, stroke sur-
vivors have often turned to alternative and complemen-
tary therapies  [3] , most of which are of unproven value or 
have not been subjected to rigorous evaluation in well-
conducted clinical trials.
 MLC601 (NeuroAiD TM ), a natural product that com-
bines herbal extracts and non-herbal components in the 
capsule form, demonstrated both neuroprotective and 
neurorestorative properties in preclinical models of focal 
and global ischemia  [4–6] . Clinical studies, which as-
sessed the benefit and safety of MLC601 in non-acute 
stroke patients using different clinical outcomes  [7–16], 
 have been published.
 More recently, MLC601 was evaluated in the CHInese 
Medicine NeuroAiD Efficacy on Stroke recovery 
(CHIMES) study, a large international, multicenter, ran-
domized, double-blind, placebo-controlled clinical trial, 
which showed a statistically nonsignificant effect of 
MLC601 at 3 months among subjects with cerebral in-
farction in the preceding 72 h (ClinicalTrials.gov: 
NCT00554723)  [17–19] . It was among the first to inves-
tigate the use of a product from natural substances that 
reduced the disability after an acute stroke in a rigorous 
manner to achieve a balance between ‘uncritical enthusi-
asm’ and ‘uninformed skepticism’.
 CHIMES-E is a planned extension study that assessed 
outcomes over the 21 months after the final CHIMES 
study assessment was made. The objective was to test the 
hypothesis that MLC601 (NeuroAiD TM ), given over the 
initial 3 months after a stroke, is superior to placebo in 
improving the functional outcome for up to 2 years 
among subjects with cerebral infarction of intermediate 
severity.
 Methods 
 Study Design and Participants 
 The trial protocol was previously published  [20] . Briefly, all 
subjects randomized to either MCL601 or placebo in CHIMES 
were eligible for inclusion in CHIMES-E: aged 18 or older who had 
an ischemic stroke of intermediate severity defined as National 
Institutes of Health Stroke Scale (NIHSS) of 6–14 in the preceding 
72 h with neuroimaging findings compatible with cerebral infarc-
tion and a pre-stroke modified Rankin Scale (mRS)  ≤ 1. Subjects 
were excluded if they had withdrawn consent from all participa-
tion and follow-up in CHIMES. This study was approved by the 
respective institutional review board of study sites.
 Randomization, Treatment and Blinding 
 Subjects were randomly assigned in the CHIMES Study to re-
ceive a 3-month course of either MLC601 or placebo at a dose of 
4 capsules 3 times daily. MLC601 and matching placebo were pro-
vided by Moleac (Singapore). Each 400 mg MLC601 capsule con-
tained 9 herbal components (extracts derived from raw herbs 
 consisting of Radix astragali, Radix salvia mitorrhizae, Radix pae-
oniae rubra, Rhizoma chuanxiong, Radix angelicae sinensis, Car-
thamus tinctorius, Prunus persica, Radix polygalae and Rhi-
zoma acoritatarinowii) and 5 non-herbal components (Hirudo, 
Eupolyphaga seu steleophaga, Calculus bovis artifactus, Buthus 
martensii and Cornu saigaetataricae). Placebo included 4 constit-
uents (barley, dried ripe fruit, noodle fish and citric acid) known 
to have no active effect but gave a similar appearance, smell, and 
taste as the active treatment  [17, 18] . To avoid center and process-
of-care effects, subjects were entered into the trial using random-
ized blocks of 4 and 6 (stratified by center) based on a 1: 1 treat-
ment allocation. Blinding of the subjects, their caregivers, investi-
gators, study staff, sponsor, and study project coordinators to 
treatment allocation was maintained into the CHIMES-E study 
phase.
 Throughout the CHIMES and CHIMES-E studies, all subjects 
were allowed to receive standard stroke care, including antiplatelet 
therapy, control of vascular risk factors, and appropriate rehabili-
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tation as prescribed by the treating physician. We have previously 
demonstrated that post-stroke use of concomitant secondary pre-
vention treatments and rehabilitation in CHIMES were high and 
similar between the two treatment groups  [19] .
 Study Procedures 
 Eligible subjects were contacted by telephone. After explaining 
the nature of the study using a standardized telephone script, ver-
bal consent was obtained prior to performing the assessments that 
were carried out at month 6 (±1 month), month 12 (±1 month), 
month 18 (±1 month) and month 24 (±1 month).
 Assessments were performed using a questionnaire. Data col-
lected included mRS, Barthel Index (BI), self-report of having re-
ceived rehabilitation, self-report of having received traditional 
Chinese medicine (TCM), self-report of having suffered a new vas-
cular event (e.g. stroke, myocardial infarction), self-report of de-
veloping other significant illnesses, and occurrence of death and 
its cause.
 Power Calculation 
 We assumed that 35% of moderately severe stroke patients 
would be dead (mRS 6) and 25% would be dependent, distributed 
among mRS 2–5, at 2 years  [21–23] . We expected an overall 30% 
dropout rate after 2 years follow-up of the 1,100 patients recruited 
into CHIMES. Having mRS data available in 770 subjects at year 2 
would have a power of 89% with two-sided type I error of 5% in 
detecting a cumulative odds ratio (OR) of 1.5 for the MLC601 
group. Even with a sample size of 606, we could ensure at least 80% 
power. Furthermore, a sample size of 816 would provide 80% pow-
er with 5% type 1 error in detecting a 10% increase in the propor-
tion of subjects attaining mRS  ≤ 1 in the treated group compared 
to 40% in the placebo group.
 Study Endpoints and Efficacy Analyses 
 Efficacy analyses were based on the intention-to-treat princi-
ple. The primary endpoint was mRS at month 24. The difference 
in distribution of subjects within each range of mRS between pla-
Randomized in CHIMES (n = 1,100)
Withdrawn after
randomization (n = 1)
Non-participating
sites (n = 14)
Non-participating
sites (n = 16)
Allocated to MLC601
(n = 550)
Allocated to placebo
(n = 549)
Potential participants
in CHIMES-E (n = 534) Potential participantsin CHIMES-E (n = 535)
Subjects with M6
data (n = 446)
Subjects with M6
data (n = 432)
Subjects with M12
data (n = 432)
Subjects with M12
data (n = 445)
Subjects with M18
data (n = 441)
Subjects with M18
data (n = 429)
Subjects with M24
data (n = 426)
LOCF (n = 431)
Per protocol (n = 343)
Subjects with M24
data (n = 436)
LOCF (n = 441)
Per protocol (n = 358)
 Fig. 1. Flow diagram of patients in CHIMES to the CHIMES-E Study. M = Month; LOCF = last observation carried forward. 
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cebo and MLC601 groups was tested using the Mann-Whitney 
U test with allowance for ties. Ordinal logistic regression using 
study groups as the independent variable was performed to pro-
vide an estimate of the OR and corresponding 95% confidence 
interval (CI) and further adjusted for potentially prognostic fac-
tors.
 Secondary endpoint measures were functional independence 
defined on mRS as a score of  ≤ 1 and on BI as a score of  ≥ 95 at 
months 6, 12, 18 and 24. Outcomes were compared using the Chi-
square test or Fisher’s exact test. Logistic regression adjusting for 
potential prognostic factors was performed.
 Sensitivity analysis based on the last observation carried for-
ward (LOCF) method by imputing 18-month mRS and per-proto-
col analyses were carried out and compared to the results of the 
main analysis. Pre-specified subgroup analyses included age, sex, 
time from stroke onset, baseline NIHSS score, and presence of cor-
tical signs on baseline NIHSS.
 Even though there was no study treatment provided in 
CHIMES-E, the long-term safety of MLC601 was assessed by the 
occurrence of any new medical condition, including death and 
vascular events defined as recurrent stroke or transient ischemic 
attack, acute coronary event, peripheral vascular disease, pulmo-
nary embolism, and sudden death, over the study period.
 Results 
 Of the 1,069 potential subjects from the CHIMES 
Study, 880 subjects were included in CHIMES-E ( fig. 1 ). 
The CHIMES-E cohort was comparable to the CHIMES 
cohort  [18] as to demographics, stroke severity, stroke 
onset to treatment time, and risk factor profile ( table 1 ). 
Month 3 mRS was similar between subjects who were in-
cluded in CHIMES-E and those who were not (ordinal 
logistic regression p = 0.8568;  table 2 ). The CHIMES-E 
study population had an overall mean age of 61.8 ± 11.3 
with 318 (36%) women and mean baseline NIHSS of 
Table 1.  Baseline characteristics of CHIMES [18] and CHIMES-E cohorts
Subjects included in CHIMES
(n = 1,099)
Subjects included in CHIMES-E
 (n = 880)
MLC601 placebo M LC601 placebo
n 550 549 446 434
Age, years 61.3 (10.8) 61.5 (11.8) 61.4 (10.9) 62.2 (11.7)
Women, n (%) 210 (38.2) 196 (35.7) 167 (37.4) 151 (34.8)
Baseline NIHSS score; median [Q1, Q3] 8 [7, 10] 8 [6, 10] 8 [7, 10] 8 [6, 10]
Pre-stroke mRS, n (%)
0 505 (91.8) 513 (93.4) 407 (91.3) 404 (93.1)
1 45 (8.2) 36 (6.6) 39 (8.7) 30 (6.9)
Stroke onset to first dose, h 48.5 (17.2) 47.4 (17.5) 48.4 (17.2) 47.8 (17.3)
Ethnicity, n (%)
Chinese 181 (32.9) 182 (33.2) 166 (37.2) 163 (37.6)
Malay 35 (6.4) 38 (6.9) 33 (7.4) 27 (6.2)
Indian 12 (2.2) 11 (2.0) 11 (2.5) 10 (2.3)
Filipino 253 (46.0) 252 (45.9) 192 (43.0) 187 (43.1)
Thai 46 (8.4) 47 (8.6) 27 (6.1) 30 (6.9)
Others 23 (4.2) 19 (3.5) 17 (3.8) 17 (3.9)
Previous history of, n (%)
Transient ischemic attack 17 (3.1) 14 (2.6) 13 (2.9) 13 (3.0)
Ischemic stroke 49 (8.9) 50 (9.1) 39 (8.7) 38 (8.8)
Hemorrhagic stroke 5 (0.9) 3 (0.6) 4 (0.9) 1 (0.2)
Myocardial infarction 14 (2.6) 20 (3.6) 13 (2.9) 17 (3.9)
Angina 13 (2.4) 23 (4.2) 12 (2.7) 22 (5.1)
Hypertension 448 (81.4) 444 (80.9) 358 (80.3) 346 (79.7)
Diabetes mellitus, insulin dependent 10 (1.8) 16 (2.9) 7 (1.6) 12 (2.8)
Diabetes mellitus, non-insulin dependent 161 (29.3) 164 (29.9) 144 (32.3) 133 (30.6)
Hyperlipidemia 264 (48.0) 267 (48.6) 226 (50.7) 218 (50.2)
Peripheral vascular disease 5 (0.9) 3 (0.6) 5 (1.1) 3 (0.7)
Smoking 255 (46.4) 247 (45.0) 204 (45.7) 195 (44.9)
Habitual alcohol intake 158 (28.7) 157 (28.6) 123 (27.6) 119 (27.4)
 Data are number (%) or mean (standard deviation). NIHSS = National Institute of Health Stroke Scale; mRS = modified Rankin Scale.
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8.6  ±  2.5. The treatment and placebo groups were bal-
anced in baseline characteristics at the time of inclusion 
in CHIMES. They were likewise similar in terms of sub-
sequent rehabilitation and intake of any TCM over the 
study period ( table 3 ).
 Unadjusted OR for the primary end-point for 24-month 
mRS by ordinal logistic regression was 1.09 (95% CI 0.86–
1.39, p = 0.456). Multivariable ordinal logistic regression 
showed an OR of 1.08 (95% CI 0.85–1.37, p = 0.543) after 
adjusting for prognostic factors, that is, age (p < 0.001), sex 
(p = 0.005), stroke onset to study treatment (p = 0.331), 
baseline NIHSS (p < 0.001), and pre-stroke mRS (p < 
0.001). Analyses using LOCF and per protocol population 
showed qualitatively similar results ( fig. 2 ).
 Adjusted OR for achieving mRS of  ≤ 1 at month 24 was 
in favor of MLC601 but it did not reach statistical signifi-
cance. However, MLC601 was significantly associated 
with increased odds of attaining functional independence 
Table 2.  Comparison of month 3 mRS scores from the CHIMES study of subjects who were subsequently included in CHIMES-E 
(n = 880) and those who were not (n = 189)
Month 3 mRS in
CHIMES study
Subjects included in CHIMES-E  Subjects not included in CHIMES-E
total MLC601 placebo total MLC601 placebo
Missing 42 20 22 42 22 20
0 131 (15.6) 66 (15.5) 65 (15.8) 24 (16.3) 11 (16.7) 13 (16.0)
1 264 (31.5) 146 (34.3) 118 (28.6) 49 (33.3) 20 (30.3) 29 (35.8)
2 194 (23.2) 96 (22.5) 98 (23.8) 30 (20.4) 11 (16.7) 19 (23.5)
3 138 (16.5) 62 (14.6) 76 (18.4) 26 (17.7) 16 (24.2) 10 (12.3)
4 76 (9.1) 40 (9.4) 36 (8.7) 17 (11.6) 8 (12.1) 9 (11.1)
5 8 (1.0) 3 (0.7) 5 (1.2) 1 (0.7) 0 (0.0) 1 (1.2)
6 27 (3.2) 13 (3.1) 14 (3.4) 0 (0.0) 0 (0.0) 0 (0.0)
 Data are number (%). mRS = Modified Rankin Scale.
MLC601
(n = 446)
Placebo
(n = 434)
Received rehabilitation since last contact at
6 months 78 (17.5) 80 (18.4)
12 months 56 (12.6) 56 (12.9)
18 months 45 (10.1) 42 (9.7)
24 months 38 (8.5) 40 (9.2)
Placement of subjects at
6 months
Acute unit 1 (0.2) 2 (0.5)
Rehabilitation unit 1 (0.2) 1 (0.2)
Nursing home 7 (1.6) 5 (1.2)
Home 409 (91.7) 395 (91.0)
Other 26 (5.8) 27 (6.2)
12 months
Acute unit 6 (1.3) 3 (0.7)
Rehabilitation 
unit
0 (0.0) 1 (0.2)
Nursing home 9 (2.0) 7 (1.6)
Home 403 (90.4) 396 (91.2)
Other 24 (5.4) 23 (5.3)
MLC601
(n = 446)
Placebo
(n = 434)
18 months
Acute unit 1 (0.2) 4 (0.9)
Rehabilitation unit 0 (0.0) 0 (0.0)
Nursing home 10 (2.2) 5 (1.2)
Home 397 (89.0) 389 (89.6)
Other 31 (7.0) 29 (6.7)
24 months
Acute unit 4 (0.9) 3 (0.7)
Rehabilitation unit 0 (0.0) 2 (0.5)
Nursing home 12 (2.7) 6 (1.4)
Home 387 (86.8) 379 (87.3)
Other 31 (7.0) 34 (7.8)
Intake of traditional Chinese medicine since last contact at
6 months 36 (8.1) 45 (10.4)
12 months 33 (7.4) 40 (9.2)
18 months 24 (5.4) 29 (6.7)
24 months 25 (5.6) 25 (5.8)
 Data are number (%).
Table 3.  Rehabilitation, intake of any traditional Chinese medicine and placement among subjects in CHIMES-E
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defined as mRS of  ≤ 1 at 6, 12, and 18 months as well as BI 
of  ≥ 95 at 6 months ( fig. 2 ). Subgroup analyses showed no 
treatment heterogeneity for the primary outcome. We 
performed a sensitivity analysis using 3 models: imputing 
CHIMES month 3 data for subjects with no CHIMES-E 
data, assuming all subjects with no CHIMES-E data as 
having the worst outcome, and assuming all subjects with 
no CHIMES-E data as having the best outcome. As ex-
pected, there were variations in statistical significance, 
but the trajectories of the point estimates over time were 
all qualitatively similar ( table 4 ).
 Long-term safety of a 3-month treatment course of 
MLC601 was assessed by the reporting of the occurrence 
of death and medical events over the study period. By 
month 24, rates of death and occurrence of any vascular 
event were similar between study groups. Other medical 
events classified according to organ system are presented 
in  table  5 . In particular, there was no difference in the 
rates of renal or hepatic adverse events. Neoplasm was 
reported in 4 subjects each for the MLC601-treated (gy-
necologic 1, lung 2, urinary 1) and placebo-treated (para-
thyroid 1, lung 2, urinary 1) groups.
mRS shift at 24 months
 Unadjusted
 Adjusted
 LOCF
 Per protocol
mRS dichotomy 0–1 vs. 2–6
 Month 6
 Month 12
 Month 18
 Month 24
Barthel Index
Barthel Index ?95 vs. <95
 Month 6
 Month 12
 Month 18
 Month 24
878
877
870
862
1.55 (1.14, 2.10)
1.22 (0.89, 1.66)
1.31 (0.95, 1.79)
1.36 (0.99, 1.86)
1.09 (0.86, 1.39)
1.08 (0.85, 1.37)
1.09 (0.86, 1.39)
1.05 (0.80, 1.37)
1.49 (1.11, 2.01)
1.41 (1.05, 1.90)
1.36 (1.01, 1.83)
1.29 (0.96, 1.74)
862
862
872
701
878
877
870
862
Subgroups
 Age ?60 years
 Age >60 years
 Male
 Female
 Baseline NIHSS 6 to 9
 Baseline NIHSS 10 to 14
 Stroke to first dose ?48 h
 Stroke to first dose >48 h
 Cortical sign at baseline
 No cortical sign at baseline
398
464
550
312
507
354
447
415
296
566
0.97 (0.68, 1.38)
1.08 (0.78, 1.49)
1.15 (0.85, 1.55)
1.02 (0.69, 1.51)
1.04 (0.76, 1.42)
1.32 (0.91, 1.91)
0.98 (0.71, 1.37)
1.23 (0.88, 1.74)
1.23 (0.82, 1.84)
1.10 (0.82, 1.47)
Interaction
p-value
0.241
0.527
0.076
0.613
0.246
0.2 1.0 5.0
Favors placebo Favors MLC601
Modified Rankin Scale n OR (95% CI)
 Fig. 2. Forest plot of outcomes and sub-
groups by intention-to-treat analyses. 
LOCF = Last observation carried forward. 
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 Discussion 
 Our study is a planned follow-up of the largest ran-
domized placebo-controlled clinical trial of traditional 
medicine in ischemic stroke. In this study, an initial 
3-month treatment with MLC601 did not demonstrate a 
statistically significant benefit at 3 months  [18] and simi-
larly at 24 months. However, the odds of achieving func-
tional independence as defined by an mRS  ≤ 1 were sig-
nificantly increased at 6 months and persisted up to 18 
months after a stroke. The absolute benefit of achieving 
an independent functional outcome (mRS  ≤ 1) was 80 per 
1,000 treated patients at 6 months, 71 per 1,000 at 12 
months, 64 per 1,000 at 18 months, and 53 per 1,000 at 24 
months.
 Precedents in stroke trials of treatments that showed 
‘delayed’ statistical benefit beyond the period at which the 
effect was expected have been reported. Intravenous re-
combinant tissue plasminogen activator, although only 
administered once during the hyperacute phase of stroke 
as a revascularization procedure, failed to reach statistical 
significance on NIHSS at 24 h, but improved functional 
outcomes at 3 months  [24] . MLC601 has been shown in 
tissue and animal models to enhance the self-reparative 
processes in the brain after an injury in addition to its 
neuroprotective effects  [4, 5]. Such processes take time 
and thus it is plausible that effects may not be apparent 
very soon after the initiation of treatment. Benefits may 
accrue and appear only some time after the treatment has 
been started. In an earlier pilot study in which stroke pa-
tients were treated with MLC601 for only 1 month, im-
provement in motor recovery appeared at 2 months, al-
though we have to admit that the sample size for that 
study was small  [10] .
 Apart from efficacy, CHIMES-E provided further safe-
ty data on MLC601 even when combined with other 
stroke treatments used in the clinical setting, showing no 
increase in the rates of delayed adverse event that may oc-
cur even after treatment was discontinued, such as malig-
nancies and chronic effects on renal or hepatic function. 
Such long-term efficacy and safety information are not 
commonly available in many stroke trials. While the use 
of natural products such as MLC601 may have greater ac-
ceptance in cultures already using herbal remedies, such 
Table 4.  Sensitivity analysis for mRS dichotomy 0–1 using 3 models: imputing CHIMES month 3 data for subjects with no CHIMES-E 
data, assuming all subjects with no CHIMES-E data as having the worst outcome, and assuming all subjects with no CHIMES-E data as 
having the best outcome
mRS 0–1 LOCF from CHIMES 
month 3 data
Assuming worst outcome 
for missing data
Assuming best 
outcome for missing data
Month 6 1.24 (0.97–1.58) 1.37 (1.07–1.76) 1.25 (0.97–1.60)
Month 12 1.20 (0.94–1.54) 1.33 (1.04–1.70) 1.22 (0.95–1.57)
Month 18 1.18 (0.92–1.50) 1.29 (1.00–1.65) 1.20 (0.93–1.54)
Month 24 1.13 (0.89–1.45) 1.23 (0.96–1.58) 1.16 (0.90–1.50)
 mRS = Modified Rankin Scale; LOCF = last observation carried forward.
Table 5.  Number of subjects experiencing death and medical 
events in CHIMES-E
NeuroAiD
(n = 446)
Placebo
(n = 434)
Death 28 29
Vascular event* 56 55
Central nervous system,
non-vascular 24 19
Cardiac, non-vascular 5 3
Hepatobiliary 2 2
Renal 10 9
Hematologic 12 8
Dermatologic 2 0
Endocrine 9 5
Gastrointestinal 18 16
Gynecologic 2 0
Infection 23 26
Ophthalmologic 0 1
Orthopedic 7 7
Psychiatric 4 1
Pulmonary 3 6
Rheumatologic 6 7
Urinary 5 6
 * Recurrent stroke or transient ischemic attack, acute coronary 
event, pulmonary embolism, peripheral vascular disease, sudden 
death.
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as in Asia where there is a high stroke burden, the perfor-
mance of this study according to international standards 
also have an impact on its use in other parts of the world.
 Our study has some important implications for future 
stroke trials. It is well known that stroke patients sponta-
neously recover to a great extent during the first three 
months after a stroke, especially among the less severe 
cases  [25] . Demonstrating effects on recovery during this 
period may be more difficult than at a later time when 
spontaneous improvement is less likely to confound the 
study. Recently, it has also been shown that transition 
from independence in activities of daily living to depen-
dency between 3 and 12 months after a stroke is not in-
significant  [26] . A follow-up period of 3 months, as is the 
case in many acute stroke trials, may be of insufficient 
duration to demonstrate a treatment effect and may re-
quire strict patient selection as we have shown in our co-
hort  [27, 28] . Longer assessments after the initial short-
course therapy may help in further evaluating stroke 
treatments, such as those using neuroprotectants, previ-
ously thought to be ineffective. The transition between 
brain injury and repair is highly regulated and complex 
such that many therapeutic targets have temporal profiles 
 [29, 30] . Treatment candidates should consider this tran-
sition by carefully defining the optimal time for adminis-
tration as well as the time of assessment of effects.
 Moreover, our findings emphasize the importance of 
using the most suitable statistical model for analyzing tri-
al cohorts based on their predicted behavior in the study 
 [31] . The functional gains seen in our study appear to be 
limited to a higher proportion of subjects attaining full 
independence as measured by mRS assuming the efficacy 
of the investigational compound. This is still clinically rel-
evant to stroke patients and caregivers, with more subjects 
returning to normal living and less caregiver burden. The 
mRS shift analysis did not show significant differences in 
outcome between treatment groups, although the point 
estimates were in favor of MLC601 and could conceivably 
reach statistical significance with a much larger sample 
size. The inability to detect statistical significance on ordi-
nal analysis was likely due to not having the expected ef-
fect size across the range of mRS and not taking into ac-
count possible misclassifications of outcomes in a categor-
ical scale. Such errors have been shown to severely 
underestimate the sample size calculation  [32, 33] . While 
using the full range of mRS is attractive, it may be fraught 
with uncertainty in assessments, making dichotomization 
more appealing as it leads to lower error rates  [33] .
 As previously reported, patients included in CHIMES 
were relatively of milder severity many of whom have re-
covered well by three months even in the placebo group 
 [18] . Having few patients in the more severe spectrum of 
mRS may have affected the power to detect significant 
‘shifts’ across scores between treatment groups as previ-
ously alluded to by others  [31] . On the other hand, the 
benefits in our cohort clustered at a single transition make 
dichotomy analysis more advantageous in demonstrating 
a difference in achieving near complete to complete re-
covery.
 We previously hypothesized that a longer duration of 
treatment and follow-up of patients may improve the 
sensitivity of detecting the effects on long-term recovery 
 [18] . We have also previously shown a reduction in early 
vascular events with MLC601 treatment for 3 months 
 [19] . In CHIMES-E, we noted consistently favorable 
treatment effect for all assessment time points but the 
largest effect was seen at 6 months with a gradual decline 
at 24 months; however, no difference in rates of vascular 
events was observed. This suggests a wearing off of effect 
of the initial 3-month treatment course, both for func-
tional recovery and even more so for secondary preven-
tion, and suggests a need for longer treatment duration or 
continuous treatment.
 There are limitations and possibly unrecognized con-
founders that could be potential sources of type I error in 
our study. We were able to achieve only 80% follow-up of 
the original subjects included in CHIMES. Nonetheless, 
this was more than expected in the power calculation and 
is no worse than other long-term cardiovascular studies, 
particularly when study treatment was no longer contin-
ued  [34–39] . Furthermore, we investigated if attrition 
bias existed in our cohort. The baseline characteristics 
and month 3 mRS were comparable between subjects 
with and those without CHIMES-E data, while sensitivity 
analyses showed the same relationship between treat-
ment and outcomes for all time points. Another possible 
limitation is that we performed telephone rather than in-
person assessments. Face-to-face mRS assessment have 
been reported to be prone to bias and inter-rater variabil-
ity, which may be improved by using structured inter-
views  [40–42] . Telephone assessments of mRS and BI 
likely suffer from the same shortcomings, although some 
have shown them to be as reliable as face-to-face evalua-
tions  [43–46] . On the other hand, telephone-based as-
sessments improve subject retention and minimize miss-
ing data in longitudinal studies  [47] . Trial-related train-
ing for assessing mRS, BI, and NIHSS in the CHIMES-E 
study was not performed. It is possible that assessment or 
ascertainment bias may have occurred in our study, al-
though investigators were experienced stroke trialists.
 CHIMES-E – Long-Term Efficacy of 
MLC601 in Stroke 
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 The main strength of CHIMES-E was that it was based 
on a well-conducted multicenter acute stroke trial with a 
large sample size and performed in a blinded, placebo-
controlled manner, with a long-term follow-up. The end-
points were robust and were used in most stroke trials. 
The results were consistent at various time points and 
seen on 2 indices, that is, mRS and BI.
 In conclusion, while the benefits of a 3-month treat-
ment with MLC601 did not reach statistical significance 
for the primary endpoint at 2 years, the odds of achieving 
functional independence defined as mRS  ≤ 1 at 6 months 
was significantly increased and persisted up to 18 months 
after a stroke. A longer duration of treatment and follow-
up beyond the conventional 3-month study period should 
be considered in stroke trials of agents with putative neu-
roprotective and restorative effects.
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